| Prev Close | 2.48 |
| Open | 2.50 |
| Day Low/High | 2.49 / 2.60 |
| 52 Wk Low/High | 1.90 / 7.78 |
| Volume | 138.84K |
Adamas Pharmaceuticals, Inc. (ADMS)
2.60
0.12
4.80
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 28.16B |
| Market Cap | 72.09M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Rules of Biotech Investing Change, and So Must Biotech Investors
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Versartis Pops, DBV Wild Ride Continues -- Biotech Movers
Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.
Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Playing Biotech After FDA Approval
Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.
Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples
Winning FDA approval isn't always a win.
Winning FDA Approval Isn't Always a Win
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
Hurricane Harvey, Now a Category 2, Heads for Oil-Rich Gulf Coast
Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.
3 Biotechs to Buy This Summer
These companies will do well, despite a range bound sector.
Biotech Bargain Bin Bursts With Bounty
This sector is one of the few areas of the market where you'll find myriad compelling values.
Fitting Finish to a Tough Year
Today's action was disappointing and frustrating.
